Implementation of New Imaging Techniques, Biomarkers and New Treatments in Prostate Cancer

Dear Colleagues,

We are living in an era of unprecedented development in prostate cancer, both in the diagnosis of the disease with the introduction of multiparametric magnetic resonance imaging and positron emission tomography (PET) with new radiotracers (PSMA, fluciclovine, etc.), as well as with the implementation of molecular biomarkers (serum and urinary markers, genomic classifiers, genes associated with alterations in DNA repair, mismatch repair, etc.) which have diagnostic and prognostic implications that can allow us to personalize the treatment for our patients.

The number of therapeutic options for castration-resistant and metastatic prostate cancer has substantially increased over the last few years. The traditional treatment for these patients (i.e., androgen deprivation therapy) is now considered suboptimal. Several randomized phase III studies have reported a significant clinical benefit in terms of overall survival and quality of life with treatments that combine androgen deprivation therapy with docetaxel, abiraterone, enzalutamide, apalutamide, darolutamide, immunotherapy, radium 223 and lutecium-PSMA. Moreover, in patients with oligometastatic disease or low tumor burden, metastasis-directed therapy combined with systemic treatments is another area of growing interest.

This Special Issue aims to explore the technological and therapeutic advances that already have a clinical use or that can transform the diagnostic and treatment paths of prostate cancer in the coming years.

Dr. Felipe Couñago
Dr. Thomas Zilli
Dr. Fernando López Campos
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.